Relapsed or Refractory Acute Myeloid Leukemia (AML)
Oncology·MeSH: Recurrence
3 drugs in development·2 companies·2 clinical trials
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| komzifti | Kura Oncology, Inc. (KURA) |
Phase 1(1)
| Drug | Company |
|---|---|
| ACLX-002 | Arcellx, Inc. (ACLX) |
Preclinical(1)
| Drug | Company |
|---|---|
| ACLX-004 | Arcellx, Inc. (ACLX) |
Compare drugs
Frequently asked questions
How many drugs are in development for Relapsed or Refractory Acute Myeloid Leukemia (AML)?
BioSniper tracks 3 drugs in development for Relapsed or Refractory Acute Myeloid Leukemia (AML) across 2 companies.
How many clinical trials target Relapsed or Refractory Acute Myeloid Leukemia (AML)?
There are 2 clinical trials targeting Relapsed or Refractory Acute Myeloid Leukemia (AML) tracked by BioSniper.
Deep-dive into Relapsed or Refractory Acute Myeloid Leukemia (AML)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis